KAT2A / GCN5 antibody | knockout validation | Abcam ab217876

This is a knockout-validated antibody summary, based on the publication "Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

KAT2A / GCN5 antibody | knockout validation | Abcam ab217876 figure 1
Figure 1. The protein levels of KAT2A in A498 cells with KAT2A overexpression or deficiency were validated via Western blotting. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Abcam

Antibody: KAT2A / GCN5

Catalog number: ab217876

Summary: Rabbit monoclonal antibody against a recombinant fragment of KAT2A. Reacts with mouse and human. It is predicted to work with rat. Suitable for western blot, immunoprecipitation and ChIP.

Validation Method

Western blot

Sample

WT and KAT2A KO A498 cells.

Blocking agent

5% non-fat dry milk for 1 h.

Primary incubation

1:2,000 dilution overnight.

Secondary incubation

1:5,000 dilution peroxidase-labeled anti-rabbit antibodies for 1 h.

Detection

ECL + plusTM Western Blotting system kit (cat. no. RPN2232; Amersham).

References
  1. Guo Y, Liu B, Liu Y, Sun W, Gao W, Mao S, et al. Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma. Front Cell Dev Biol. 2021;9:690796 pubmed publisher